Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

Phase 1 Completed 15 enrolled University of Florida National Institutes of Health (NIH) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of oral Dichloroacetate (DCA) in the treatment of recurrent malignant brain tumors (RMBTs). RMBTs are defined as either: 1) malignant tumors, originating in the brain, that have recurred at least once or 2) malignant tumors originating elsewhere in the body that have spread to the brain at least once. Otherwise, there are no limitations to the number of prior recurrences. There are no limitations to the number or types of prior therapies.

Timeline

Start: 2010-04
Primary completion: 2014-03
Completion: 2014-03

Publications

Results Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs. 2014 Jun;32(3):452-64. doi: 10.1007/s10637-013-0047-4. Epub 2013 Dec 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	DICHLOROACETIC ACID	Small molecule	4 mg/kg	Oral
Comparator	DICHLOROACETIC ACID	Small molecule	12.5 mg/kg	Oral

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

Summary

Timeline

Publications

Drugs

Indications